Evidence map›Paper›PMID 39757428›Full record

ArticleAging cell2025

Immunotherapeutic targeting of aging-associated isoDGR motif in chronic lung inflammation.

Pazhanichamy Kalailingam, SoFong Cam Ngan, Ranjith Iyappan, Afra Nehchiri, Khalilatul-Hanisah Mohd-Kahliab, Benjamin Sian Teck Lee, Bhargy Sharma, Radek Machan, Sint Thida Bo, Emma S Chambers and 15 more

Abstract read
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Carotid arteries in cerebral small vessel disease and dementia.Acta neuropathologica communications · 2026
    Article
  2. Article
  3. Repair of Isoaspartyl Residues by PCMT1 and Kidney Fibrosis.Journal of the American Society of Nephrology : JASN · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Pazhanichamy KalailingamCenter for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-7689-275X
SoFong Cam NganFaculty of Applied Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Ranjith IyappanFaculty of Applied Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Afra NehchiriFaculty of Applied Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Khalilatul-Hanisah Mohd-KahliabSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Benjamin Sian Teck LeeSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Bhargy SharmaSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Radek MachanSCELSE, Nanyang Technological University, Singapore, Singapore.
Sint Thida BoSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Emma S ChambersCentre for Immunobiology, the Blizard Institute, Bart's and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0003-0990-8835
Val A FajardoFaculty of Applied Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Rebecca E K MacphersonFaculty of Applied Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Jian LiuFaculty of Applied Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Panagiota KlentrouFaculty of Applied Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Evangelia Litsa TsianiFaculty of Applied Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Kah Leong LimLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
I Hsin SuSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Yong-Gui GaoSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
A Mark RicharCardiovascular Research Institute, National University Health System, Singapore, Singapore.
Raj N KalariaInstitute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK.
Christopher P ChenMemory, Aging and Cognition Centre, National University Health System, Singapore, Singapore.
Cynthia BalionDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Dominique de KleijnDepartment of Vascular Surgery, UMC Utrecht, Utrecht, The Netherlands.
Neil E McCarthyCentre for Immunobiology, the Blizard Institute, Bart's and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-4330-4747
Siu Kwan SzeSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.ORCID 0000-0002-5652-1687

Funding

Canada Research Chairs CRC-2020-00263CIHR PJT-186091
6 · The paper itself

Abstract

Accumulation of damaged biomolecules in body tissues is the primary cause of aging and age-related chronic diseases. Since this damage often occurs spontaneously, it has traditionally been regarded as untreatable, with typical therapeutic strategies targeting genes or enzymes being ineffective in this domain. In this report, we demonstrate that an antibody targeting the isoDGR damage motif in lung tissue can guide immune clearance of harmful damaged proteins in vivo, effectively reducing age-linked lung inflammation. We observed age-dependent accumulation of the isoDGR motif in human lung tissues, as well as an 8-fold increase in isoDGR-damaged proteins in lung fibrotic tissues compared with healthy tissue. This increase was accompanied by marked infiltration of CD68+/CD11b + macrophages, consistent with a role for isoDGR in promoting chronic inflammation. We therefore assessed isoDGR function in mice that were either naturally aged or lacked the isoDGR repair enzyme. IsoDGR-protein accumulation in mouse lung tissue was strongly correlated with chronic inflammation, pulmonary edema, and hypoxemia. This accumulation also induced mitochondrial and ribosomal dysfunction, in addition to features of cellular senescence, thereby contributing to progressive lung damage over time. Importantly, treatment with anti-isoDGR antibody was able to reduce these molecular features of disease and significantly reduced lung pathology in vivo.

Indexed as

AgingImmunotherapyPneumoniaAmino Acid MotifsAnimalsCellular SenescenceChronic DiseaseHumansLungMiceMice, Inbred C57BLantibodyimmune clearanceimmunotherapyinflammationisoDGRlung fibrosis

Identifiers

PMID39757428
PMCPMC11984686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.